BMP4-GPX4 Axis Mitigates Ferroptosis and Enhances Stem Cell Differentiation in Experimental Glaucoma

Study Background and Research Question

Glaucoma, particularly forms associated with elevated intraocular pressure (IOP), remains a leading cause of irreversible blindness worldwide. A critical feature of glaucoma pathogenesis is the progressive degeneration of retinal ganglion cells (RGCs), which ultimately leads to loss of visual function. Recent literature identifies ferroptosis—a form of regulated, iron-dependent cell death characterized by lipid peroxidation and reactive oxygen species (ROS) accumulation—as a significant contributor to RGC demise in glaucoma. Overcoming RGC loss is a major therapeutic challenge, prompting exploration of cell replacement strategies such as retinal stem cell (RSC) transplantation. However, the efficacy of these approaches depends on the survival and differentiation of transplanted cells within the hostile, oxidative environment of the glaucomatous retina.

The central research question addressed by Fang et al. (Human Molecular Genetics, 2025) is whether modulating the bone morphogenetic protein 4 (BMP4) and glutathione peroxidase 4 (GPX4) signaling axis can reduce ferroptosis and improve the differentiation and survival of RSCs in a mouse model of high-IOP glaucoma.

Key Innovation from the Reference Study

The innovation in this study lies in mechanistically linking BMP4-GPX4 signaling to both the mitigation of ferroptosis in RGCs and the enhancement of RSC differentiation post-transplantation. By establishing that BMP4 upregulation leads to increased GPX4 expression—a key antioxidant enzyme that reduces lipid ROS—the authors propose a dual neuroprotective and regenerative mechanism. This approach not only preserves endogenous RGCs but also optimizes the integration and maturation of transplanted RSCs, offering a refined strategy for treating neurodegenerative ocular conditions.

Methods and Experimental Design Insights

To model glaucoma-related excitotoxicity and oxidative stress, the researchers utilized intravitreal administration of NMDA (N-Methyl-D-aspartic acid), a potent NMDA receptor agonist, to induce selective RGC injury and simulate high-IOP conditions. Immunofluorescence labeling for Brn3a, a canonical RGC marker, confirmed RGC loss consistent with glaucoma pathology. Subsequent bioinformatics analysis of publicly available gene expression datasets (GEO: GSE236302) indicated enrichment of stem cell pluripotency pathways and upregulation of BMP4.

The authors validated these findings with quantitative PCR and Western blot analyses, demonstrating increased expression of BMP4 and downstream SMAD1/3/5 signaling components in retinas from the glaucoma model. To quantify the ferroptosis phenotype, they performed a series of established biochemical and histological assays:

• ROS detection (immunofluorescence-based assays)
• Glutathione (GSH) quantification
• Malondialdehyde (MDA) measurement (marker of lipid peroxidation)
• Ferrous iron (Fe²⁺) detection
• Western blotting for ferroptosis marker proteins (ACSL4, GPX4, SLC7A11)

Finally, the impact of BMP4-GPX4 modulation was evaluated in the context of RSC transplantation, analyzing both the ferroptosis phenotype and the differentiation efficiency of transplanted cells into mature RGCs.

Protocol Parameters

• NMDA-induced glaucoma model: Intravitreal injection of NMDA to induce RGC loss and simulate high-IOP glaucoma; refer to the reference study for detailed dosing and timepoints.
• Immunofluorescence for RGC loss: Brn3a antibody labeling to quantify RGC degeneration.
• qPCR and Western blotting: Analysis of BMP4, SMAD1/3/5, and ferroptosis-related proteins post-injury and intervention.
• Biochemical assays: ROS, GSH, MDA, and Fe²⁺ quantification to profile oxidative stress and ferroptosis.
• Stem cell transplantation: Intraretinal injection of RSCs following glaucoma induction, with subsequent evaluation of differentiation and survival.

Core Findings and Why They Matter

Key results from the study demonstrate that BMP4 expression is significantly upregulated in NMDA-induced glaucoma, both at the mRNA and protein levels. Importantly, BMP4-GPX4 pathway activation leads to:

• Reduced ROS and MDA levels, indicating attenuation of oxidative stress.
• Elevated glutathione, promoting cellular redox balance.
• Lower Fe²⁺ accumulation, limiting the iron-dependent lipid peroxidation that drives ferroptosis.
• Downregulation of ACSL4 and upregulation of GPX4 and SLC7A11, consistent with reduced ferroptotic activity.
• Enhanced survival and differentiation of transplanted RSCs into the RGC lineage, as evidenced by increased expression of RGC markers.

Collectively, these outcomes indicate that BMP4-GPX4 pathway modulation not only mitigates the ferroptotic environment detrimental to neuronal survival but also supports the regenerative potential of stem cell therapies. This dual mechanism addresses two major barriers—cell death and poor differentiation—that have limited the clinical translation of RSC transplantation in glaucoma.

Comparison with Existing Internal Articles

Several internal resources further contextualize the experimental use of NMDA for modeling excitotoxicity and oxidative stress in neurodegeneration. For example, the article "NMDA (N-Methyl-D-aspartic acid): Mechanistic Leverage and..." outlines how NMDA-induced models are foundational in probing the interplay between excitotoxicity and oxidative injury, particularly in retinal and cortical neurons. Similarly, "NMDA in Translational Neurodegeneration: Mechanism to Model" highlights NMDA as a reproducible trigger for ferroptosis and synaptic vulnerability, supporting its use in studies like Fang et al. By integrating these perspectives, this reference study leverages established NMDA protocols but uniquely advances the field by demonstrating how BMP4-GPX4 modulation can be layered onto such models to dissect and potentially intervene in ferroptotic processes during stem cell therapy.

Furthermore, internal articles such as "NMDA (N-Methyl-D-aspartic acid): Scenario-Driven Solution..." and "Benchmark NMDA Receptor..." discuss the critical role of NMDA receptor agonists in calcium influx measurement and oxidative stress assays—parameters closely mirrored in the study's methodology. These resources reinforce the value of NMDA-based glaucoma models for translational research.

Limitations and Transferability

While the data robustly support the BMP4-GPX4 axis as a modulator of ferroptosis and stem cell differentiation in a mouse glaucoma model, several limitations merit consideration. The NMDA-induced model, though widely used, does not fully recapitulate the chronic, multifactorial etiology of human glaucoma. The study's reliance on acute injury and stem cell transplantation in immunocompetent mice may not capture the complexities of the human retinal microenvironment, including immune responses and long-term integration challenges.

Moreover, the translation of BMP4-GPX4 modulation to clinical settings will require careful titration of pathway activation to avoid off-target effects, given BMP4's pleiotropic roles in development and tissue homeostasis. Further research is warranted to determine whether similar neuroprotective and differentiation-promoting effects can be achieved in chronic or genetically diverse models of glaucoma, and whether combinatorial therapies might be necessary.

Research Support Resources

Researchers interested in modeling excitotoxicity, oxidative stress, and ferroptosis in retinal or other neuronal systems can implement protocols similar to those described in this study using high-purity NMDA (N-Methyl-D-aspartic acid), available as SKU B1624 from APExBIO. This reagent is validated for direct, receptor-mediated induction of calcium influx and excitotoxic injury, supporting workflows for oxidative stress assays and neurodegenerative disease models. For reproducible, mechanistically precise modeling of RGC injury and subsequent intervention studies, NMDA remains a standard tool in both basic and translational neuroscience.